SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $41

HC Wainwright & Co. maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and raises the price target from $40 to $41.

Benzinga · -
HC Wainwright & Co. maintains Karyopharm Therapeutics (NASDAQ: KPTI) with a Buy and raises the price target from $40 to $41.